UAE It takes a great deal to become number one in a field, but the harder challenge is staying there Joe Henein, CEO of Dubai-headquartered NewBridge Pharmaceuticals, has built one of MENA’s most distinctive specialty pharma platforms over the past 15 years. With over 300 people across MENA, a pan-regional footprint…
USA More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000 orphan drug designations (ODD) granted by the FDA since then, it is estimated that only around five percent of rare…
MEA As global pharmaceutical strategies continue to shift, Ali Sleiman reflects on how Genesys Pharmaceuticals is being built as a disciplined execution platform for the Middle East and Africa. The interview explores how distributor-led models, portfolio selectivity, and strong infrastructure shape access to innovation, including in rare diseases, against an increasingly…
See our Cookie Privacy Policy Here
